CAJ | 학술논문

目的：探讨参芪扶正注射液联合DCF方案对晚期胃癌患者的疗效影响。方法：纳入139例晚期胃癌患者，分为治疗组和对照组，两组基线情况均衡可比，治疗组给予DCF方案联合参芪扶正注射液，对照组给予DCF方案。结果：治疗组较对照组在客观缓解率上（ORR）无明显差异，但疾病控制率（DCR）明显提高，分别为72.9%和52.2%，差异有统计学意义。结论：参芪扶正注射液联合化疗治疗晚期胃癌，能明显降低化疗的毒副反应，值得进一步研究。
목적：탐토삼기부정주사액연합DCF방안대만기위암환자적료효영향。방법：납입139례만기위암환자，분위치료조화대조조，량조기선정황균형가비，치료조급여DCF방안연합삼기부정주사액，대조조급여DCF방안。결과：치료조교대조조재객관완해솔상（ORR）무명현차이，단질병공제솔（DCR）명현제고，분별위72.9%화52.2%，차이유통계학의의。결론：삼기부정주사액연합화료치료만기위암，능명현강저화료적독부반응，치득진일보연구。
Objective: To investigate clinical efficacy of the Shenqi Fuzheng injection plus DCF chemotherapy in patients with advanced gastric cancer. Methods: 139 patients were divided into the treatment group and the control group, baselines in both was comparable. The both were given DCF chemotherapy, the treatment was treated by the Shenqi Fuzheng injection more. Results: The differences of overall remission rates in both were not significant, control rate in the treatment increased obviously. The DCR in the treatment and the control was 72.9% and 52.2% respectively, the difference was statistically significant. Conclusion: The Shenqi Fuzheng injection plus DCF chemotherapy was effective on advanced gastric cancer, could decrease side reactions in chemotherapy, and was worthy of further study.